JC Answer: In mid-August Medafor Inc., a small, privately held company selling $45M worth of hemostatic agents annually, agreed to be purchased by C.R. Bard Inc. (BCR) for more than $200M, plus up to $80M based upon sales milestones. Cryolife owns more than 8% of Medafor, dating back to a 2010 selling arrangement, which should bring in a gain of $14.2M to Cryolife. Plus, Cryolife will be eligible for $6.71M for future sales milestones.
Response: Assuming BCR acquires Medafor, CRY would receive a material amount of cash, as stated above by Jeff. IMO, if CRY were to use a substantial amount of this newly found cash to buy back CRY stock, I would guess that CRY should be able to support the CRY share price at the $6/share, or higher, price level. Hence, IMO at the present time I find CRY to be 'reasonably valued'. Not under priced, not over priced, but probably priced about right, at least until more is know about the future of PerClot.
I'm sure that SA will have an interesting spin on all of this during the October 2013 conference call.